Vanda Pharmaceuticals (VNDA) announced the first dose in the first-in-human clinical trial to evaluate the safety and tolerability of VCA-894A, an antisense oligonucleotide therapeutic, for a patient with a rare variant in the IGHMBP2 gene causing Charcot-Marie-Tooth disease Type 2S.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VNDA:
- Vanda Approves Key Proposals at Annual Meeting
- Vanda Pharmaceuticals assumed with an Overweight at Cantor Fitzgerald
- Vanda Pharmaceuticals: Strong Financial Performance and Strategic Growth Justify Buy Rating
- Vanda Pharmaceuticals’ Earnings Call: Growth Amid Challenges
- Vanda Pharmaceuticals Reports Q1 2025 Financial Results